To determine if differential expression of MYC or MYCBP was present in ALK+ NSCLC compared to other mutant-driver lung cancer subtypes, we measured basal mRNA and protein expression of MYC and MYCBP in a panel of cell lines that included three ALK+ NSCLC cell lines (H3122, H2228, and STE-1), a ROS1 gene fusion cell line (HCC78), two mutant EGFR cell lines (H1650 and HCC827) and two KRAS cell lines (A549 and H460) and NRAS (H1299) NSCLC cell lines (Figure 2A, 2B and Supplementary Figure 2). This evidence concerns the gene MYCBP and lung carcinoma.